Genomed SA (GEN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Genomed SA

Telemedycyna Polska SA

Why is Genomed SA ?

Poor Management Efficiency with a low ROE of 8.65%

The company has been able to generate a Return on Equity (avg) of 8.65% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of 9.55% and Operating profit at 37.19% over the last 5 years

The company has declared negative results in Mar'2026 after 4 consecutive positive quarters

INTEREST(HY) At PLN 0.08 MM has Grown at 508.53%
RAW MATERIAL COST(Y) Grown by 66.86% (YoY)
DEBTORS TURNOVER RATIO(HY) Lowest at 9.11 times

Underperformed the market in the last 1 year

The stock has generated a return of 1.55% in the last 1 year, much lower than market (Poland WIG) returns of 29.94%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Genomed SA for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Genomed SA

2.34%

-0.09

71.13%

Poland WIG

29.57%

1.74

17.24%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.55%

EBIT Growth (5y)

37.19%

EBIT to Interest (avg)

1.04

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.47

Sales to Capital Employed (avg)

2.50

Tax Ratio

5.22%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

21.90%

ROE (avg)

8.65%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.84

EV to EBIT

7.18

EV to EBITDA

6.00

EV to Capital Employed

4.37

EV to Sales

0.98

PEG Ratio

0.20

Dividend Yield

ROCE (Latest)

60.83%

ROE (Latest)

25.20%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at PLN 3.11 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 14.67 times

NET PROFIT(9M)

Higher at PLN 3.01 MM

CASH AND EQV(HY)

Highest at PLN 11.63 MM

-19What is not working for the Company

INTEREST(HY)

At PLN 0.08 MM has Grown at 508.53%

RAW MATERIAL COST(Y)

Grown by 66.86% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 9.11 times

OPERATING PROFIT(Q)

Lowest at PLN 0.22 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 3.28 %

PRE-TAX PROFIT(Q)

Lowest at PLN -0.05 MM

NET PROFIT(Q)

Lowest at PLN -0.05 MM

EPS(Q)

Lowest at PLN -0.04

Here's what is working for Genomed SA

Operating Cash Flow

Highest at PLN 3.11 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (PLN MM)

Inventory Turnover Ratio

Highest at 14.67 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Cash and Eqv

Highest at PLN 11.63 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Genomed SA

Interest

At PLN 0.08 MM has Grown at 508.53%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (PLN MM)

Pre-Tax Profit

At PLN -0.05 MM has Fallen at -119.85%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (PLN MM)

Net Profit

At PLN -0.05 MM has Fallen at -120.37%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (PLN MM)

Operating Profit

Lowest at PLN 0.22 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (PLN MM)

Operating Profit Margin

Lowest at 3.28 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at PLN -0.05 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (PLN MM)

Net Profit

Lowest at PLN -0.05 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (PLN MM)

EPS

Lowest at PLN -0.04

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (PLN)

Debtors Turnover Ratio

Lowest at 9.11 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 66.86% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales